Editorial
Treatment of idiopathic pulmonary fibrosis: the rise and fall of corticosteroids

https://doi.org/10.1016/S0002-9343(01)00622-2Get rights and content

References (15)

  • D.W. Mapel et al.

    Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future

    Chest

    (1996)
  • Idiopathic pulmonary fibrosisdiagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS)

    Am J Respir Crit Care Med

    (2000)
  • Flaherty KR, Toews GB, Lynch JP III, et al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of...
  • L.C. Watters et al.

    A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis

    Am Rev Respir Dis

    (1986)
  • M. Selman et al.

    Idiopathic pulmonary fibrosisprogress in understanding its pathogenesis and implications for therapy

    Ann Intern Med

    (2001)
  • J.L. Myers

    NSIP, UIP, and the ABCs of idiopathic interstitial pneumonias

    Eur Respir J

    (1998)
  • A.L.A. Katzenstein et al.

    Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification

    Am J Respir Crit Care Med

    (1998)
There are more references available in the full text version of this article.

Cited by (32)

  • Idiopathic interstitial pneumonias

    2019, Difficult to Diagnose Rare Diffuse Lung Disease
  • Targeting of discoidin domain receptor 2 (DDR2) prevents myofibroblast activation and neovessel formation during pulmonary fibrosis

    2016, Molecular Therapy
    Citation Excerpt :

    IPF patients have a median survival of ∼2–3 years after diagnosis because of an irreversible loss of lung function and respiratory failure.1 Although a variety of inflammatory insults are associated with the development of IPF, an undeniable fact is that this type fibrotic disorder is clinically recalcitrant to treatment with immunosuppressive agents,2 leading to the recent shift of concept for IPF treatment away from anti-inflammation toward antifibrosis.3 However, although there has been a huge rise in clinical trials with antifibrotic drugs during the past decade, it was until recently that two pharmacological agents were approved for the treatment of moderate IPF.4

  • Idiopathic Interstitial Pneumonias

    2015, Murray and Nadel's Textbook of Respiratory Medicine: Volume 1,2, Sixth Edition
  • Pivotal role of cathepsin K in lung fibrosis

    2004, American Journal of Pathology
    Citation Excerpt :

    A number of experimental approaches have been investigated in clinical trials including the modulation of key cytokines and growth factors, and treatment with corticosteroids or immunosuppressants. In a number of patients these have little effect on clinical outcome.46–48 Therefore, alternative approaches to prevent the development of lung fibrosis should be explored.49

View all citing articles on Scopus
View full text